- Trials with a EudraCT protocol (288)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
288 result(s) found for: SARS coronavirus.
Displaying page 11 of 15.
EudraCT Number: 2020-001367-88 | Sponsor Protocol Number: 25032020 | Start Date*: 2020-04-14 | |||||||||||
Sponsor Name:Department of Infectious diseases | |||||||||||||
Full Title: Efficacy and safety of novel treatment options for adults with COVID-19 pneumonia. A double-blinded, randomized, multi-stage, 6-armed placebo-controlled trial in the framework of an adaptive trial ... | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001265-36 | Sponsor Protocol Number: UCDCRC/20/01 | Start Date*: 2020-05-05 | |||||||||||
Sponsor Name:University College Dublin | |||||||||||||
Full Title: A multicentre, prospective, randomised trial comparing standard of care (SOC) alone, SOC plus hydroxychloroquine monotherapy or SOC plus a combination of hydroxychloroquine and azithromycin in the ... | |||||||||||||
Medical condition: SARS-CoV-2 PCR-positive population | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000492-36 | Sponsor Protocol Number: HOPECOVID-19 | Start Date*: 2021-05-31 | |||||||||||
Sponsor Name:UCLouvain | |||||||||||||
Full Title: Home and Outpatients Precocious Eradication of COVID-19 | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000063-51 | Sponsor Protocol Number: mRNA-1273-P305 | Start Date*: 2024-01-01 |
Sponsor Name:ModernaTX, Inc. | ||
Full Title: A Phase 2/3, Randomized, Observer-blind, Active-controlled, Multicenter Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison with mRNA-1273 (Prototype) Booster ... | ||
Medical condition: SARS-CoV-2 | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2021-000344-21 | Sponsor Protocol Number: MP1032-CT05 | Start Date*: 2021-07-21 | ||||||||||||||||||||||||||
Sponsor Name:MetrioPharm AG | ||||||||||||||||||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PROOF-OF-CONCEPT, PHASE IIA STUDY OF MP1032 PLUS STANDARD OF CARE VS STANDARD OF CARE IN THE TREATMENT OF HOSPITALIZED PATIENTS WITH MOD... | ||||||||||||||||||||||||||||
Medical condition: Moderate to severe coronavirus disease 2019 (COVID 19) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: FR (Completed) HU (Completed) ES (Ongoing) BG (Completed) IT (Completed) RO (Ongoing) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-006082-11 | Sponsor Protocol Number: ADG20-TRMT-001 | Start Date*: 2021-06-02 | |||||||||||
Sponsor Name:Adagio Therapeutics Inc. | |||||||||||||
Full Title: A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Treatment of Ambulatory Participants with Mild or Moderate COVID-19 (STAMP) | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Prematurely Ended) DE (Prematurely Ended) HU (Completed) BG (Prematurely Ended) PL (Prematurely Ended) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001782-37 | Sponsor Protocol Number: PО-COV-III-20 | Start Date*: 2020-11-07 | |||||||||||
Sponsor Name:NPO Petrovax Pharm, LLC | |||||||||||||
Full Title: A multi-centre, adaptive, randomized, double-blind, placebo-controlled comparative clinical trial of the safety and efficacy of 12 mg Polyoxidonium®, lyophilizate solution for injections (NPO Petro... | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000618-32 | Sponsor Protocol Number: GNC-501 | Start Date*: 2022-09-29 | ||||||||||||||||
Sponsor Name:GENEURO SA | ||||||||||||||||||
Full Title: Temelimab as a Disease Modifying Therapy in Patients with Neurological, Neuropsychological, and Psychiatric (=Neuropsychiatric) Symptoms in Post-COVID-19 or Postacute Sequelae of COVID-19 (PASC) Sy... | ||||||||||||||||||
Medical condition: Postacute Sequelae of COVID-19 (PASC) Syndrome | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001696-32 | Sponsor Protocol Number: GC2004 | Start Date*: 2020-05-08 | ||||||||||||||||
Sponsor Name:Instituto Grifols, S.A | ||||||||||||||||||
Full Title: A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) plus Standard Medical Treatment (SMT) versus SMT alo... | ||||||||||||||||||
Medical condition: Patients with Mild to Moderate Coronavirus Disease (COVID-19) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-002011-21 | Sponsor Protocol Number: MARACOVID | Start Date*: 2020-06-02 |
Sponsor Name:Fundación para la Investigación e Innovación Biomédica del Hospital Universitario Infanta Leonor y Sureste (FIIB) | ||
Full Title: Bicentric, phase 2, randomized, open-label study to evaluate the efficacy and safety of maraviroc associated with standard treatment in hospitalized patients with pulmonary SARS-CoV-2 infection (CO... | ||
Medical condition: COVID-19 Pneumonia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-002895-38 | Sponsor Protocol Number: C4671005 | Start Date*: 2021-08-23 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF-07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTI... | |||||||||||||
Medical condition: Coronavirus Disease 2019 (COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) CZ (Completed) HU (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001904-41 | Sponsor Protocol Number: GETAFIX-2020 | Start Date*: 2020-05-20 | |||||||||||
Sponsor Name:NHS Greater Glasgow and Clyde [...] | |||||||||||||
Full Title: Glasgow Early Treatment Arm FavIpiravir : A randomized controlled study of favipiravir as an early treatment arm in COVID-19 patients | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001405-23 | Sponsor Protocol Number: Ruxo-Sim-20 | Start Date*: 2020-06-05 | |||||||||||
Sponsor Name:Fundación de Investigación HM Hospitales | |||||||||||||
Full Title: Randomized phase II clinical trial of ruxolitinib plus simvastatin in the prevention and treatment of respiratory failure of COVID-19.Ruxo-Sim-20 clinical trial. | |||||||||||||
Medical condition: COVID19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001203-16 | Sponsor Protocol Number: LIBERATE | Start Date*: 2020-05-06 | |||||||||||||||||||||
Sponsor Name:Guy's and St Thomas' NHS Foundation Trust [...] | |||||||||||||||||||||||
Full Title: Lipid ibuprofen versus standard of care for acute hypoxaemic respiratory failure due to COVID-19: a multicentre, randomised, controlled trial | |||||||||||||||||||||||
Medical condition: COVID-19; respiratory failure; hypoxaemia. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-001767-86 | Sponsor Protocol Number: COVIRL-002 | Start Date*: 2020-06-25 | |||||||||||
Sponsor Name:University College Dublin | |||||||||||||
Full Title: An open-label, multi-centre, randomised trial comparing different doses of single-dose tocilizumab in adults with severe, non-critical, PCR-confirmed COVID-19 infection with evidence of progressive... | |||||||||||||
Medical condition: COVID-19 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001505-22 | Sponsor Protocol Number: BST-COVID-01 | Start Date*: 2020-04-23 | |||||||||||
Sponsor Name:Banc de Sang i Teixits | |||||||||||||
Full Title: Double-blind, randomized, parallel, placebo-controlled pilot clinical trial, nested in a prospective cohort observational study, for the evaluation of the efficacy and safetyof two doses of WJ-MSC ... | |||||||||||||
Medical condition: Acute respiratory distress syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002259-39 | Sponsor Protocol Number: TL-895-202 | Start Date*: 2020-09-23 | |||||||||||
Sponsor Name:Telios Pharma, Inc. | |||||||||||||
Full Title: A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 with Standard Available Treatment versus Standard Available Treatment for the Treatment of COVID-19 in Patients with Cancer | |||||||||||||
Medical condition: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in patients with cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: RO (Prematurely Ended) HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000627-12 | Sponsor Protocol Number: CV43140 | Start Date*: 2021-06-01 | |||||||||||
Sponsor Name:F. Hoffmann La Roche Ltd. | |||||||||||||
Full Title: A MULTICENTER, OBSERVATIONAL, 6 MONTH FOLLOW-UP STUDY OF PATIENTS WITH COVID 19 PREVIOUSLY ENROLLED IN A RO7496998 (AT-527) STUDY | |||||||||||||
Medical condition: Coronavirus disease 2019 (COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) PT (Prematurely Ended) DK (Completed) DE (Completed) IT (Prematurely Ended) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005332-27 | Sponsor Protocol Number: WA43811 | Start Date*: 2022-01-31 |
Sponsor Name:F. Hoffmann-La Roche Ltd | ||
Full Title: A PHASE Ib, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF TOCILIZUMAB IN PEDIATRIC PATIENTS HOSPITALIZED WITH COVID-19 | ||
Medical condition: Coronavirus disease 2019 (COVID-19) | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Ongoing) IT (Prematurely Ended) GR (Completed) FR (Completed) DE (Completed) PL (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-001971-33 | Sponsor Protocol Number: CORIVER | Start Date*: 2020-06-02 |
Sponsor Name:Carmen Hidalgo | ||
Full Title: Pragmatic study "CORIVER": Ivermectin as antiviral treatment for patients infected by SARS-COV2 (COVID-19) | ||
Medical condition: SARS-COV2 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
